Skip to main content
Access Bio, Inc. logo

Access Bio, Inc. — Investor Relations & Filings

Ticker · 950130 ISIN · KR8840090003 LEI · 335800Q5TV77F4L9Q648 KO Manufacturing
Filings indexed 247 across all filing types
Latest filing 2023-08-02 Legal Proceedings Report
Country IN India
Listing KO 950130

About Access Bio, Inc.

https://accessbio.net/

Access Bio, Inc. is a company dedicated to the prevention and early diagnosis of infectious diseases through the research, development, and manufacturing of in vitro diagnostic solutions. Its portfolio includes rapid diagnostic tests (RDTs), immunochemical diagnostics, biosensors, and molecular diagnostic products. The company is recognized for commercializing high-quality tests to combat significant global health threats, including malaria, COVID-19, HIV, and HPV. With a large-scale manufacturing capacity, Access Bio distributes its products globally, serving as a key partner in global health, particularly in the fight against often-neglected diseases.

Recent filings

Filing Released Lang Actions
소송등의판결ㆍ결정(주주총회소집허가)
Legal Proceedings Report Classification · 1% confidence The document is a formal disclosure regarding a court decision ('소송등의판결ㆍ결정') concerning a request for permission to convene a general meeting of shareholders. It details the case name, court, decision date, and the outcome (dismissal). This falls under the category of legal proceedings and regulatory disclosures regarding litigation.
2023-08-02 Korean
전환가액의조정(제5회차)
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of shares, and the underlying calculation methodology based on market price fluctuations. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2023-07-10 Korean
소송등의판결ㆍ결정(일정금액이상의청구)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure regarding a legal proceeding (a lawsuit/arbitration case) involving Access Bio. It details the status of a legal dispute, specifically the withdrawal of a counterclaim, and provides case numbers, parties involved, and the outcome. This fits the definition of a Legal Proceedings Report (LTR) as it pertains to significant legal matters and regulatory disclosures.
2023-07-03 Korean
[기재정정]소송등의제기ㆍ신청(경영권분쟁소송)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from Access Bio regarding a legal proceeding ('소송 등의 제기ㆍ신청') specifically related to a management dispute ('경영권 분쟁 소송') involving a request for shareholder list inspection and copying. Since this document details a specific legal action and court-related filing, it falls under the category of Legal Proceedings Report (LTR).
2023-06-14 Korean
전환가액의조정(제5회차)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from Access Bio regarding the adjustment of the conversion price for its 5th series convertible bonds due to a decline in the market price of its shares. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under the 'Capital/Financing Update' category as it directly relates to financing activities and the terms of debt-to-equity conversion.
2023-06-12 Korean
소송등의제기ㆍ신청(경영권분쟁소송)(주주총회소집허가)
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure regarding a legal proceeding ('소송 등의 제기ㆍ신청') involving a management dispute and a request for permission to convene an extraordinary general meeting of shareholders. Since it details a specific legal action/lawsuit filed against the company, it falls under the category of Legal Proceedings Report.
2023-06-05 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.